Slawomir Jeka Selected Research

CT-P10

12/2019	Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
2/2019	Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
8/2018	Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
8/2017	Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
3/2017	A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
1/2017	Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Slawomir Jeka Research Topics

Disease

13	Rheumatoid Arthritis 11/2022 - 01/2008
2	Psoriatic Arthritis 01/2021 - 01/2021
2	Ankylosing Spondylitis 01/2021 - 10/2013
2	Nausea 04/2020 - 10/2009
2	Necrosis 03/2017 - 03/2015
1	Pain (Aches) 01/2021
1	Anemia 04/2020
1	Headache (Headaches) 04/2020
1	Respiratory Tract Infections (Respiratory Tract Infection) 04/2020
1	Tuberculosis (Tuberculoses) 10/2013
1	Infections 10/2009
1	Hypertension (High Blood Pressure) 10/2009
1	Human Influenza (Influenza) 10/2009
1	Neck Pain (Cervicalgia) 10/2009
1	Chest Pain (Chest Pains) 10/2009
1	Migraine Disorders (Migraine) 10/2009
1	Fatigue 10/2009
1	Dysmenorrhea (Menstrual Pain) 10/2009
1	Dizziness (Lightheadedness) 10/2009

Drug/Important Bio-Agent (IBA)

7	Biosimilar PharmaceuticalsIBA 01/2021 - 10/2013
6	CT-P10IBA 12/2019 - 01/2017
6	Rituximab (Mabthera)FDA Link 12/2019 - 01/2017
4	Adalimumab (Humira)FDA Link 11/2022 - 04/2020
2	CT-P17IBA 11/2022 - 01/2021
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2017 - 03/2015
2	Pharmaceutical PreparationsIBA 10/2013 - 10/2009
2	Prednisone (Sone)FDA LinkGeneric 07/2010 - 01/2008
1	upadacitinibIBA 01/2021
1	secukinumabIBA 01/2021
1	Citric Acid (Citrate)FDA LinkGeneric 01/2021
1	Janus Kinase InhibitorsIBA 01/2021
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2021
1	fenebrutinibIBA 04/2020
1	Agammaglobulinaemia Tyrosine KinaseIBA 04/2020
1	CNTO6785IBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Methotrexate (Mexate)FDA LinkGeneric 01/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 03/2015
1	CT-P13IBA 10/2013
1	Infliximab (Remicade)FDA Link 10/2013
1	AntibodiesIBA 10/2013
1	Tryptamines (Triptans)IBA 10/2009
1	frovatriptan (Allegro)FDA Link 10/2009
1	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2008
1	GlucocorticoidsIBA 01/2008
1	TabletsIBA 01/2008

Therapy/Procedure

3	Therapeutics 01/2018 - 01/2008
1	Biological Therapy 08/2017
1	Chronotherapy 07/2010